Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Moreover, a significant reduction in both systolic and diastolic blood pressure has been observed in individuals following ADF regimens [72]
Ask the brand directly to confirm the endorser credential shown on the landing page, if it matters to you
Key Highlights Orforglipron (Eli Lilly) * 13.6% weight loss in Phase 2 * 2.1% HbA1c reduction * Highest efficacy among the three molecules in Phase 2 * Subsequently confirmed efficacy in Phase 3 with up to 14.7% weight loss * First and only FDA-approved oral small-molecule GLP-1 receptor agonist (Foundayo) Elecoglipron (AstraZeneca) * 11.8% weight loss * 1.9% HbA1c reduction * Strong Phase 2b results * Currently advancing into a global Phase 3 program Aleniglipron (Structure Therapeutics) * 12.1% weight loss * 1.5% HbA1c reduction * Encouraging efficacy with ongoing Phase 3 development Phase 2 Efficacy Comparison Weight Loss * Orforglipron: 13.6% * Aleniglipron: 12.1% * Elecoglipron: 11.8% HbA1c Reduction * Orforglipron: 2.1% * Elecoglipron: 1.9% * Aleniglipron: 1.5% As Structure Therapeutics expanded their testing into the ACCESS II trial and evaluated higher doses (specifically escalation protocols reaching 180 mg and 240 mg), the efficacy numbers jumped significantly
A.WillettR
US$ 21.27
US$ 25.62
US$ 21.43
US$ 20.54
US$ 25.88
US$ 24.79
US$ 24.29
